Next-generation sequencing of tumor DNA from patients with colorectal cancer revealed genetic alterations that were linked to different survival and treatment outcomes in an analysis led by a University of North Carolina Lineberger Comprehensive Cancer Center researcher. The findings, published in the Journal of Clinical Oncology, could help define strategies to more effectively treat colorectal … Continued
Tag: colon cancer
UNC Lineberger Comprehensive Cancer Center researchers are working to better understand the cell-to-cell signaling that can cause precancerous polyps in the colon when signaling goes awry. In a study published in the open-access journal eLife, they describe the role of a key tumor suppressor protein called APC in helping to keep cells in the colon crypts from growing out of control.
In a study published in Nature Medicine, UNC Lineberger Comprehensive Cancer Center researchers report their findings of just how a certain tumor-suppressing protein helps prevent colon cancer. With this discovery, the researchers believe they’ve found a possible drug target for colon cancer patients who lack the tumor suppressor.
Ebix, Inc., today announced that the annual Ebix Charity Challenge, will be held in Greensboro, North Carolina on February 7, 2015. All proceeds from the 5th Annual Ebix Charity Challenge will benefit the UNC Lineberger Comprehensive Cancer Center, where America No. 1 John Isner’s mother, Karen, was successfully treated during her two battles with colon cancer.
A non-invasive test that includes detection of the genetic abnormalities related to cancer could significantly improve the effectiveness of colon cancer screening, according to research published by a team of scientists including David Ransohoff, MD, professor of medicine at the UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center member.
Hy Muss, MD, and Debra Bynum, MD, co-authored an editorial in the July 20, 2012 issue of the Journal of Clinical Oncology.
Chapel Hill – A family of proteins is yielding new information about how it contributes to the development of gastrointestinal disease and cancer. A team of UNC scientists reports that in pre-clinical models, the absence of a protein called NLRP12 significantly increases susceptibility to colitis-associated colon cancer.
In 2008 UNC and Harvard University’s Brigham and Women’s Hospital in Boston were selected by the U.S. Agency for Healthcare Research and Quality to carry out accelerated practical studies examining the comparative effectiveness of cancer treatments. The collaboration is called the Cancer Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Comparative Effectiveness Consortium.